Oct 16,2023

Incyte Announces New Data from across its Oncology Portfolio to be Presented at ESMO Congress 2023

Incyte (Nasdaq:INCY) today announced that abstracts featuring new data from its oncology portfolio will be presented at the upcoming European Society for Medical Oncology (ESMO) Congress 2023, held October 20-24 in Madrid. Presentations, including results from studies of retifanlimab and capmatinib, focused on patients with endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer, will showcase Incyte's continued efforts to pursue innovative therapies for patients with cancer.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 18,2023

Oncology PHR service “Welby MyCarte ONC” exhibited at the 61st Annual Meeting of the Japanese Society for Cancer Therapy

Welby is pleased to announce exhibition of their oncology PHR service "Welby MyCarte ONC" at the "61st Annual Meeting of the Japanese Society for Cancer Therapy." from October 19th (Thursday) to 21st (Saturday), 2023. MyCarte ONC was developed with the concept of putting the information necessary for cancer treatment in the palm of your hand. It is a platform service that enables the centralization of feedback treatment information and the collection of information according to the patient's symptoms and treatment details.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Oct 18,2023

PathAI Announces Launch of AIM-TumorCellularity (AIM-TC), an AI-Based Tumor Cellularity Assessment Product, to Inform Advanced Molecular Testing

PathAI, a global leader in AI-powered pathology, today announced the launch of AIM-TumorCellularity (AIM-TC), the latest algorithm product available for use by laboratories using the AISight Image Management System (IMS). AIM-TC enables automated assessment of tumor cellularity, or tumor fraction, which is utilized to determine if there is sufficient tumor tissue to support advanced next generation sequencing (NGS) testing. Insufficient tumor DNA is a common failure mode in comprehensive genomic profiling and results in the destruction of precious tissue without molecular biomarker information to inform care decisions. AIM-TC is currently available in Non-Small Cell Lung Cancer (NSCLC) and will be launched in 12 additional tumor types (including breast cancer, colorectal cancer, prostate cancer, gastric cancer, pancreatic cancer, ovarian cancer, melanoma, renal cell carcinoma, hepatocellular carcinoma, and urothelial carcinoma) in the coming months.

PRODUCT

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Jun 22,2023

Honeysuckle Health partners with Osara Health

Honeysuckle Health has partnered with Osara Health, formerly known as CancerAid, to educate and support patients suffering from cancer. From today, Honeysuckle client and health partner, nib, will offer the Cancer Coach Program to their members at no additional cost. The program offers one-on-one support from a qualified Health Coach, who will support, listen, motivate and empower members to take action and make decisions to improve their everyday wellbeing.

COLLABORATION PARTNERSHIP

#institution

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 01,2023

Osara Health joins the CancerX founding members

Osara Health is proud to announce they've become a founding member of CancerX, joining forces with more than 90 reputable organizations that are participating in this initiative. CancerX, co-hosted by Moffitt Cancer Center, Digital Medicine Society (DiMe), Office for the National Coordinator for Health Information Technology (ONC), and Office of the Assistant Secretary for Health (OASH), is a public-private partnership originating from President Joe Biden's Cancer Moonshot initiative. It aims to cut cancer death rates by 50% in 25 years and enhance the patient experience.

View Analyst & Ambassador Comments
Go to original news
Oct 17,2023 TOP STORY

ClearView partners with Osara Health to support customers affected by cancer

Listed life insurance company, ClearView Wealth Limited, has partnered with cancer support and education provider, Osara Health, to give claimants access to a digital health care program that is proven to help improve health and wellbeing. Utilising Osara Health’s Cancer Coach program, ClearView customers who have been diagnosed with cancer will gain access to professional health coaches, educational resources and practical strategies to support them on their cancer journey.

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
Feb 24,2023

AIA Australia extends cancer care program to health customers

Major life, health, and wellbeing insurer AIA Australia has extended its CancerAid program to AIA Health Insurance (AIA Health) customers after four years of seeing the program's positive impact on life insurance customers. The new partnership between AIA Health and CancerAid gives customers diagnosed with cancer access to Cancer Coach – an educational, behavioural change program that aims to support people living with cancer to take back control of their cancer care.

COLLABORATION PARTNERSHIP

#insurance

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 08,2022

New partnership with CancerAid to support CCEP Australia employees affected by cancer

As part of the partnership, CCEP’s 3,600+ employees around Australia will have confidential access to CancerAid's suite of innovative, digitally-led programs: the Coach Program and the Caregivers Program. The Coach Program is designed for people with a cancer diagnosis, helping them navigate their diagnosis through personalised coaching and award-winning technology featuring a combination of digital touch points via online modules and a mobile app for symptom tracking and community articles.

COLLABORATION PARTNERSHIP

#institution

#coaching

View Analyst & Ambassador Comments
Go to original news
Jul 03,2023

Aon New Zealand to support colleagues with cancer diagnosis through Osara Health

Aon plc (NYSE: AON), a leading global professional services firm, today announced it is working with Osara Health - formerly known as CancerAid - to provide Aon colleagues in New Zealand with support when faced with a cancer diagnosis. As one of the first arrangements of its kind in New Zealand, Aon colleagues will have confidential access to Osara Health’s two digitally led programs - the Cancer Coach Program and Cancer Caregivers Program - with the primary focus on supporting colleagues when they need it most. 

COLLABORATION PARTNERSHIP

#institution

#coaching

View Analyst & Ambassador Comments
Go to original news
Oct 10,2023

Lunit to Showcase 9 AI-based Research Results at ESMO 2023

Lunit announced the presentation of 9 studies featuring its AI pathology research at the upcoming European Society for Medical Oncology (ESMO) 2023 Congress, scheduled to be held in Madrid, Spain, from October 20 to 24, 2023. This year's collection of abstracts delves into multifaceted research, including the use of AI-powered analysis to predict treatment outcomes in different cancer types, assess HER2 expression in breast and biliary tract cancer, and streamline clinical workflows for treatment decisions in lung cancer, all utilizing the Lunit SCOPE suite.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY